

# Lipid-Lowering Treatment Selector

Charts reviewed December 2023. Full information available at [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org)

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV oral	FTR	LEN	MVC	BIC/F/TAF	CAB oral	CAB/RPV	DTG	EVG/c/F/TAF	EVG/c/F/TDF	RAL	FTC/TAF	FTC/TDF
<b>Statins</b>																						
Atorvastatin	↑822%	↑	↑290%	↑	↑490%	↓2%	↓43%	↓37%	↓	↑4%	↑	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fluvastatin	↑	↑	↑	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Lovastatin	↑	↑	↑	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pitavastatin	↑	↑ <sup>a</sup>	↑	↓26%	↓20%	↔	↓11%	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Pravastatin	↑	↑	↑	↑81%	↔	↔	↓44%	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Rosuvastatin	↑242%	↑213%	↑93%	↑48%	↑108%	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Simvastatin	↑	↑	↑	↑	↑	↔	↓68%	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
<b>Fibrates</b>																						
Bezafibrate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Clofibrate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Fenofibrate	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Gemfibrozil	↔	↓	↔	↓	↓41%	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
<b>Other</b>																						
Alirocumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Evolocumab	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
Ezetimibe	↑	↑	↑	↓↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔

**Interactions with CAB/RPV long acting injections**

Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

**Interactions with Lenacapavir**

Residual LEN may affect exposure of sensitive CYP3A4 substrates initiated within 9 months after stopping subcutaneous LEN.

**Interactions with Ibalizumab**

None

**Interactions with Abacavir (ABC), Lamivudine (3TC), Tenofovir-DF (TDF) or Zidovudine (ZDV)**

ABC: No clinically relevant interactions expected.

3TC: No clinically relevant interactions expected.

TDF: No clinically relevant interactions expected.

ZDV: No clinically relevant interactions expected.

**Colour Legend**

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

**Text Legend**

- ↑ Potential increased exposure of the lipid-lowering drug
- ↓ Potential decreased exposure of the lipid-lowering drug
- ↔ No significant effect

Numbers refer to increase or decrease in AUC as observed in drug-drug interaction studies.

**Notes**

- <sup>a</sup> Coadministration with unboosted atazanavir increased pitavastatin AUC by 31%.